All of the Group’s activities, with a focus on addressing unfulfilled medical needs and the accessibility of medicines, are backed by heavy investment in Research and Development, resulting in more than 130 portfolio products, 119 INNs, and over 4,300 MAs.
The Tecnimede Group also excels in the production of medications and has production centres in Portugal and Morocco. Atlantic Pharma and Atlas Pharm have a combined production capacity of over 50 million units.
Our purpose is the relentless pursuit of a life of dignity and health.
Our mission is to harness the combined power of medical science and technology to sustainably enhance quality of life and promote shared prosperity across diverse global communities.
- Integrity
- Loyalty
- Courage
- Perseverance
Our purpose is the relentless pursuit of a life of dignity and health.
Our mission is to harness the combined power of medical science and technology to sustainably enhance quality of life and promote shared prosperity across diverse global communities.
- Integrity
- Loyalty
- Courage
- Perseverance
Our Areas of Activity
We focus on the discovery and development of new chemical entities to address high unmet medical needs.
Our priorities include cell therapy, neuropathic pain, and anti-infectives.
Our dedicated unit focuses especially on oral care, empowering people to take an active role in their health.
Promoting individual well-being also contributes to the long-term sustainability of healthcare systems.
We operate a dedicated generics unit, Tecnigen, present in Portugal, Spain and Italy.
Through a broad portfolio of bioequivalent medicines, we support both retail and hospital channels, helping to ensure accessibility, therapeutic continuity, and the sustainability of healthcare systems.
We invest 15% of our turnoever in R&D, with over 100 specialists advancing innovative treatments in areas such as cardiovascular and metabolic diseases, nervous system disorders, and infectious diseases.
Backed by +750 patents, our work spans pharmaceutical chemistry, cell culture, and clinical research.
With two certified production units, Atlantic Pharma (Portugal) and Atlas Pharm (Morocco), we produce over 170 active ingredients across multiple pharmaceutical forms, with a combined capacity of 50 million packs/year.
We also offer manufacturing services to partners seeking competitive outsourcing solutions.
We integrate ethics, sustainability, and inclusion into every decision we make.
We are committed to generating long-term value for patients, communities, healthcare systems, and society as a whole.
The Tecnimede Group’s commercial operations are firmly rooted in its strong positioning within three key commercial areas in Portugal, alongside a direct presence in Spain, Italy, Morocco, Brazil, and Colombia. Additionally, the Group has established partnerships in nearly all European countries and across numerous regions in Africa, Asia, the Middle East, Oceania, South America, and North America, exporting to over 100 countries worldwide.
Established in 2014, the Italian subsidiary Tecnigen s.r.l. intends to consolidate its position in Italy as an innovator in the marketing of generic medications, dietary supplements, over-the-counter (OTC) medications, and medical devices.
Tecnimede Spain was founded in 1998.
At present it employs more than 50 professionals and is one of the most dynamic companies in the Spanish pharmaceutical sector. It is dedicated to the registration, marketing, and distribution of generic drugs, more than 90% of which are researched, developed, and manufactured by the Tecnimede Group.
The Tecnimede Group is 100% Portuguese and has a strong presence in the country through its companies Tecnimede, Tecnigen, Tecnimede Consumer Healthcare, and Tender & Hospital Business.
Founded in 1999, Tecnimede Morocco was the first subsidiary of the Tecnimede Group.
Tecnimede Morocco is ranked among the top 10 generic laboratories in Morocco in terms of turnover and is prominent in several fields, in particular in cardiology, urology, dermatology, respiratory medicine, and, more recently, in oncology, neurology, and rheumatology.
In 2014, the Tecnimede Group started trading in Brazil through Atlantic Pharma.
As a result of strong investment in the development of products specifically tailored to the local market, Atlantic Pharma already boasts extensive knowledge of ANVISA (the Health Regulatory Agency of Brazil) requirements and a network of key partners enabling it to offer a range of therapeutic solutions.
Altadis was created in 2015 as the result of a joint venture between the Tecnimede Group and the Colombian company Altea Farmacêutica.
Altadis is committed to being at the forefront of the latest breakthroughs in healthcare technology, producing medication for the central nervous system, cardiology, and oncology, along with immunomodulators and biotechnology.
+ 100 countries